Etretinate therapy in children with severe keratinization defects.
Keratinization defects can be very severe and disfiguring diseases. The development of retinoids such as etretinate has provided us with an effective symptomatic form of oral therapy for these skin conditions. Based on our own experience, we briefly outline the therapeutic potential of etretinate in various keratinization defects (lamellar ichthyosis, Netherton syndrome, Sjögren-Larsson syndrome, mal de Meleda and juvenile pityriasis rubra pilaris). The toxicology of etretinate is reviewed with special regard to the treatment of children. Bone changes such as premature closure of the growth line or other unacceptable side-effects have so far not been observed. Guidelines for patient selection and for the safe treatment of children are given.
Traupe
H
H
Happle
R
R
D000293:Adolescent; D001842:Bone and Bones / Q000187:drug effects; D055598:Chemical Phenomena; D002621:Chemistry; D002648:Child; D005050:Etretinate / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007633:Keratins / Q000096:biosynthesis*; D008297:Male; D012871:Skin Diseases / Q000188:drug therapy*
D005050:Etretinate; D007633:Keratins